Literature DB >> 23672440

The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab.

Charles Alderman, Jonathan Corlett, Jonathan Cullis.   

Abstract

Entities:  

Keywords:  anaemia; antibody therapy; bleeding disorders; vascular endothelial growth factor

Mesh：

Substances：

Year:  2013        PMID： 23672440     DOI： 10.1111/bjh.12377

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

1.  Intranasal bevacizumab treatment on epistaxis in hereditary haemorrhagic telangiectasia: a case report.

Authors:  Estela García-Martín; Sagrario Pernía-López; Pilar A Martínez-Ortega; Beatriz Monje; Cristina Ruiz-Martínez; María Sanjurjo-Saez
Journal:  Eur J Hosp Pharm       Date:  2017-08-16

2.  Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.

Authors:  Florian Huemer; Martin Dejaco; Christoph Grabmer; Thomas Melchardt; Daniel Neureiter; Georg Mayer; Alexander Egle; Richard Greil; Lukas Weiss
Journal:  Wien Klin Wochenschr       Date:  2017-02       Impact factor: 1.704
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.